JLB & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.7M | Buy |
12,739
+1,965
| +18% | +$1.99M | 1.68% | 23 |
|
|
2025
Q4 | $11.6M | Sell |
10,774
-516
| -5% | -$493K | 1.56% | 25 |
|
|
2025
Q3 | $8.61M | Buy |
11,290
+494
| +5% | +$368K | 1.13% | 33 |
|
|
2025
Q2 | $8.42M | Sell |
10,796
-624
| -5% | -$485K | 1.17% | 31 |
|
|
2025
Q1 | $9.43M | Sell |
11,420
-1,230
| -10% | -$1.02M | 1.32% | 31 |
|
|
2024
Q4 | $9.77M | Sell |
12,650
-1,503
| -11% | -$1.24M | 1.33% | 31 |
|
|
2024
Q3 | $12.5M | Sell |
14,153
-1,236
| -8% | -$1.11M | 1.61% | 27 |
|
|
2024
Q2 | $13.9M | Sell |
15,389
-970
| -6% | -$776K | 1.88% | 24 |
|
|
2024
Q1 | $12.7M | Sell |
16,359
-1,012
| -6% | -$720K | 1.69% | 27 |
|
|
2023
Q4 | $10.1M | Sell |
17,371
-690
| -4% | -$403K | 1.46% | 31 |
|
|
2023
Q3 | $9.7M | Sell |
18,061
-6,881
| -28% | -$3.55M | 1.52% | 29 |
|
|
2023
Q2 | $11.7M | Sell |
24,942
-1,565
| -6% | -$656K | 1.67% | 28 |
|
|
2023
Q1 | $9.1M | Buy |
26,507
+2,316
| +10% | +$781K | 1.37% | 32 |
|
|
2022
Q4 | $8.85M | Sell |
24,191
-2,962
| -11% | -$1.05M | 1.41% | 31 |
|
|
2022
Q3 | $8.78M | Sell |
27,153
-444
| -2% | -$141K | 1.56% | 30 |
|
|
2022
Q2 | $8.95M | Sell |
27,597
-1,493
| -5% | -$448K | 1.52% | 28 |
|
|
2022
Q1 | $8.33M | Sell |
29,090
-554
| -2% | -$143K | 1.25% | 34 |
|
|
2021
Q4 | $8.19M | Sell |
29,644
-1,235
| -4% | -$313K | 1.16% | 35 |
|
|
2021
Q3 | $7.13M | Sell |
30,879
-1,840
| -6% | -$454K | 1.13% | 35 |
|
|
2021
Q2 | $7.51M | Hold |
32,719
| – | – | 1.17% | 35 |
|
|
2021
Q1 | $6.11M | Sell |
32,719
-290
| -0.9% | -$56.7K | 1.01% | 37 |
|
|
2020
Q4 | $5.57M | Buy |
33,009
+149
| +0.5% | +$22.2K | 0.92% | 39 |
|
|
2020
Q3 | $4.86M | Sell |
32,860
-755
| -2% | -$117K | 0.89% | 39 |
|
|
2020
Q2 | $5.52M | Buy |
33,615
+137
| +0.4% | +$21K | 1.1% | 36 |
|
|
2020
Q1 | $4.64M | Buy |
33,478
+1,172
| +4% | +$161K | 1.1% | 34 |
|
|
2019
Q4 | $4.25M | Buy |
32,306
+233
| +0.7% | +$27K | 0.78% | 41 |
|
|
2019
Q3 | $3.59M | Buy |
32,073
+959
| +3% | +$107K | 0.71% | 40 |
|
|
2019
Q2 | $3.45M | Buy |
31,114
+2,840
| +10% | +$334K | 0.7% | 41 |
|
|
2019
Q1 | $3.67M | Buy |
28,274
+55
| +0.2% | +$6.69K | 0.77% | 41 |
|
|
2018
Q4 | $3.27M | Hold |
28,219
| – | – | 0.8% | 39 |
|
|
2018
Q3 | $3.03M | Hold |
28,219
| – | – | 0.65% | 43 |
|
|
2018
Q2 | $2.41M | Hold |
28,219
| – | – | 0.51% | 46 |
|
|
2018
Q1 | $2.18M | Hold |
28,219
| – | – | 0.47% | 49 |
|
|
2017
Q4 | $2.38M | Buy |
28,219
+258
| +0.9% | +$22K | 0.52% | 48 |
|
|
2017
Q3 | $2.39M | Sell |
27,961
-900
| -3% | -$73.8K | 0.58% | 48 |
|
|
2017
Q2 | $2.38M | Buy |
+28,861
| New | +$2.35M | 0.6% | 48 |
|
|
2016
Q4 | $2.15M | Sell |
29,189
-137
| -0.5% | -$10.2K | 0.58% | 48 |
|
|
2016
Q3 | $2.35M | Sell |
29,326
-1,304
| -4% | -$104K | 0.65% | 47 |
|
|
2016
Q2 | $2.41M | Buy |
30,630
+1,441
| +5% | +$108K | 0.68% | 47 |
|
|
2016
Q1 | $2.49M | Sell |
29,189
-1,841
| -6% | -$139K | 0.64% | 46 |
|
|
2015
Q4 | $2.61M | Sell |
31,030
-392
| -1% | -$32.5K | 0.81% | 47 |
|
|
2015
Q3 | $2.63M | Sell |
31,422
-153
| -0.5% | -$12.9K | 0.85% | 44 |
|
|
2015
Q2 | $2.64M | Sell |
31,575
-200
| -0.6% | -$15.2K | 0.82% | 43 |
|
|
2015
Q1 | $2.31M | Sell |
31,775
-179
| -0.6% | -$12.7K | 0.72% | 45 |
|
|
2014
Q4 | $2.2M | Sell |
31,954
-55
| -0.2% | -$3.71K | 0.73% | 46 |
|
|
2014
Q3 | $2.08M | Hold |
32,009
| – | – | 0.74% | 48 |
|
|
2014
Q2 | $1.99M | Sell |
32,009
-100
| -0.3% | -$5.97K | 0.72% | 48 |
|
|
2014
Q1 | $1.89M | Hold |
32,109
| – | – | 0.7% | 48 |
|
|
2013
Q4 | $1.64M | Sell |
32,109
-500
| -2% | -$25K | 0.62% | 49 |
|
|
2013
Q3 | $1.64M | Sell |
32,609
-300
| -0.9% | -$15.7K | 0.69% | 49 |
|
|
2013
Q2 | $1.62M | Buy |
+32,909
| New | +$1.79M | 0.74% | 47 |
|
Other funds holding LLY
VCM
VPM
JLB & Associates's LLY Position: Q1 2026 in Review
JLB & Associates increased its Eli Lilly (LLY) stake by 18% in Q1 2026, buying an estimated $1.99M and bringing the position to 12,739 shares worth $11.7M. The position accounts for 1.68% of the portfolio, ranked #23.
JLB & Associates first reported a position in LLY in Q2 2013 and has held it in 51 quarters since. The position peaked at $13.9M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- JLB & Associates held 12,739 shares of Eli Lilly worth $11.7M as of Q1 2026.
- JLB & Associates bought 1,965 Eli Lilly shares in Q1 2026, an estimated $1.99M.
- Eli Lilly made up 1.68% of JLB & Associates's portfolio in Q1 2026, its #23 holding.
- JLB & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 51 quarters since.
- JLB & Associates's Eli Lilly position peaked at $13.9M in Q2 2024.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on JLB & Associates's 13F filing for Q1 2026, filed 4 May 2026.